Trial Profile
Phase III clinical trial for assessment of efficacy and safety of DA-3002 (Recombinant Human Growth Hormone) for prepubertal children with idiopathic short stature in Korea.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Growth disorders; Short stature
- Focus Therapeutic Use
- 16 Nov 2017 New trial record
- 04 Nov 2017 Primary endpoint (The difference in annual height velocity (cm/year)) has been met as per the results published in the Journal of Endocrinological Investigation
- 04 Nov 2017 Results published in the Journal of Endocrinological Investigation